HC Wainwright Reiterates “Neutral” Rating for AnaptysBio (NASDAQ:ANAB)

HC Wainwright restated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB) in a research report released on Tuesday,Benzinga reports. They currently have a $19.00 price target on the biotechnology company’s stock.

A number of other equities research analysts have also commented on the stock. Truist Financial reduced their price objective on shares of AnaptysBio from $30.00 to $20.00 and set a “hold” rating on the stock in a research note on Wednesday, December 18th. UBS Group increased their price target on AnaptysBio from $23.00 to $33.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. dropped their price objective on AnaptysBio from $66.00 to $36.00 and set an “overweight” rating on the stock in a research note on Thursday, December 19th. BTIG Research lowered AnaptysBio from a “buy” rating to a “neutral” rating in a research report on Monday, December 2nd. Finally, Wells Fargo & Company lowered their target price on AnaptysBio from $56.00 to $40.00 and set an “overweight” rating for the company in a report on Thursday, December 12th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $40.08.

AnaptysBio Stock Down 0.9 %

Shares of NASDAQ:ANAB opened at $16.51 on Tuesday. The business has a fifty day simple moving average of $17.23 and a 200 day simple moving average of $26.89. AnaptysBio has a 12-month low of $12.51 and a 12-month high of $41.31. The firm has a market cap of $502.40 million and a P/E ratio of -2.72.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) EPS for the quarter, topping analysts’ consensus estimates of ($1.72) by $0.58. The company had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, equities research analysts expect that AnaptysBio will post -6.08 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, Director Ecor1 Capital, Llc acquired 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the completion of the acquisition, the director now directly owns 7,880,094 shares of the company’s stock, valued at $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 33.70% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AnaptysBio

Several large investors have recently added to or reduced their stakes in ANAB. Frazier Life Sciences Management L.P. raised its stake in shares of AnaptysBio by 2.0% in the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company’s stock worth $74,008,000 after purchasing an additional 43,598 shares during the last quarter. Point72 Asset Management L.P. raised its holdings in shares of AnaptysBio by 202.8% in the third quarter. Point72 Asset Management L.P. now owns 54,200 shares of the biotechnology company’s stock valued at $1,816,000 after purchasing an additional 36,300 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of AnaptysBio by 191.4% during the third quarter. JPMorgan Chase & Co. now owns 33,744 shares of the biotechnology company’s stock valued at $1,130,000 after purchasing an additional 22,164 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in AnaptysBio by 677.9% during the third quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its position in AnaptysBio by 55.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares in the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.